Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 01.06.2026 3 Biochem Biophys Res Commun 2 BMC Cancer 7 BMC Gastroenterol 6 Dig Dis Sci 1 Eur Radiol 2 Gastroenterology 1 Gut 1 J Clin Oncol 2 J Gastroenterol 2 J Gastroenterol Hepatol 3 J Hepatol 2 N Engl J Med 1 Nat Rev Cancer 1 Oncogene 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology 1 Transplant Proc 1 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Biochem Biophys Res Commun

1. ZHONG M, Luo X, Shi M, Zhang WJ, et al
   Reprogramming of hepatic BCAA metabolism by fructose exacerbates hepatic steatosis.
   Biochem Biophys Res Commun. 2026;825:153999.
   PubMed         Abstract available
   
   
2. MATSUSHIMA-NISHIWAKI R, Tokuda H, Kozawa O
   Cilostazol inhibits TGF-alpha-induced migration of hepatocellular carcinoma cells by activating PPARgamma.
   Biochem Biophys Res Commun. 2026;826:154014.
   PubMed         Abstract available
   
   
3. LI W, Pan M, Tang J
   Aloe-emodin ameliorates non-alcoholic fatty liver disease by regulating the ZNRF3/Wnt/beta-catenin axis and suppressing hepatic lipogenesis.
   Biochem Biophys Res Commun. 2026;827:153979.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. PENG J, Lin Q, Zhou Z, Wen Q, et al
   Potentially functional variants of CYP2A6 and ABHD12 in the arachidonic acid metabolism pathway genes predict the survival of HBV-related hepatocellular carcinoma patients.
   BMC Cancer. 2026 May 23. doi: 10.1186/s12885-026-16212.
   PubMed         Abstract available
   
   
5. HAYASHI K, Suzuki O, Ichise K, Uchida H, et al
   Efficacy and safety of carbon-ion radiotherapy for large hepatocellular carcinoma (diameter >/= 10 cm).
   BMC Cancer. 2026 May 25. doi: 10.1186/s12885-026-16096.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

6. TONG S, Xu B, Ye X, Yin J, et al
   Prognostic model for patients with hepatoid adenocarcinoma of the stomach.
   BMC Gastroenterol. 2026 May 23. doi: 10.1186/s12876-026-04933.
   PubMed         Abstract available
   
   
7. LIU Z, Lyu T, Hu L, Fan S, et al
   Feasibility, safety and accuracy of a novel robotic navigation system for cone-beam CT-guided and TACE-assisted radiofrequency ablation of hepatocellular carcinoma, a preliminary study.
   BMC Gastroenterol. 2026 May 23. doi: 10.1186/s12876-026-04956.
   PubMed         Abstract available
   
   
8. TAKAHASHI D, Maeda A, Aoyama H, Takahashi T, et al
   Combined preoperative PNI and APRI for risk stratification after curative hepatectomy for hepatocellular carcinoma.
   BMC Gastroenterol. 2026 May 25. doi: 10.1186/s12876-026-04950.
   PubMed         Abstract available
   
   
9. HASSEN TJ, Nigussie S, Teshome H, Seife H, et al
   Clinical profile and hepatocellular cancer treatment patterns in resource limited settings- a cross-sectional observational study at two tertiary referral teaching hospitals, Addis Ababa, Ethiopia.
   BMC Gastroenterol. 2026 May 25. doi: 10.1186/s12876-026-04946.
   PubMed         Abstract available
   
   
10. CHATSUNTIPRAPA S, Bannangkoon K, Tubtawee T, Ina N, et al
    Prognostic value of CT-defined sarcopenic obesity in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    BMC Gastroenterol. 2026 May 27. doi: 10.1186/s12876-026-04945.
    PubMed         Abstract available
    
    
11. JINLI W, Shiping H
    CCNA2, MAD2L1, AURKA, and PTTG1 promote proliferation and migration in hepatocellular carcinoma.
    BMC Gastroenterol. 2026 May 28. doi: 10.1186/s12876-026-04845.
    PubMed         Abstract available
    
    
12. EL-DIN ZS, Abdelsameea E, Awad SM, Arab DE, et al
    Prevalence, microbiological profile, and outcomes of spontaneous bacterial and fungal peritonitis in Egyptian patients with liver cirrhosis.
    BMC Gastroenterol. 2026;26:326.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

13. HAN F, Cui C, Cui J, Zang S, et al
    Silencing Clusterin Could Attenuate the Cell Properties of HCV Core Protein-Expressing HCC Cell Line.
    Dig Dis Sci. 2025 Nov 25. doi: 10.1007/s10620-025-09560.
    PubMed         Abstract available
    
    
14. CHOI G, Jesudian AB, Saab S
    Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision.
    Dig Dis Sci. 2025 Nov 21. doi: 10.1007/s10620-025-09537.
    PubMed         Abstract available
    
    
15. LIANG Y, Hu N, Xia X, Li F, et al
    Exploring Transcriptomic and MRI-Derived Parameters Correlations in NAFLD Fibrosis: Insights from a Rat Model.
    Dig Dis Sci. 2026;71:1972-1986.
    PubMed         Abstract available
    
    
16. NJEI B, Al-Ajlouni YA, Lemos SY, Ugwendum D, et al
    AI-Based Models for Risk Prediction in MASLD: A Systematic Review.
    Dig Dis Sci. 2026;71:1987-2014.
    PubMed         Abstract available
    
    
17. NASEEM Z, Prado R, Chatterjee A, Sierra L, et al
    Do Improving Hepatic Biomarkers Predict Spontaneous Stone Passage? A Retrospective Analysis of ERCP Yield in Suspected Choledocholithiasis.
    Dig Dis Sci. 2026 May 29. doi: 10.1007/s10620-026-09963.
    PubMed         Abstract available
    
    
18. YE W
    Recalibrating EVendo for Atezolizumab-Bevacizumab Era Hepatocellular Carcinoma.
    Dig Dis Sci. 2026 May 25. doi: 10.1007/s10620-026-09962.
    PubMed        
    
    

    
    Eur Radiol

19. YANG S, Sartoris R, Teyssier Y, Bone A, et al
    Auto-LSN: fully automated liver surface nodularity quantification in CT based on deep learning for the evaluation of advanced chronic liver disease.
    Eur Radiol. 2026;36:5043-5052.
    PubMed         Abstract available
    
    

    
    Gastroenterology

20. KIM GA, Jang H, Kim MY, Park JH, et al
    Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes.
    Gastroenterology. 2026;170:1571-1583.
    PubMed         Abstract available
    
    
21. KWO PY, Masuoka HC, Schaefer EA, Friedman LS, et al
    Evaluation of Abnormal Liver Biochemical Test Results.
    Gastroenterology. 2026;170:1457-1472.
    PubMed         Abstract available
    
    

    
    Gut

22. CARDENAS BI, Naranjo Suarez S, Baroja I, Mendez A, et al
    CPEB4 deficiency promotes vasculogenic mimicry and resistance to anti-angiogenic therapy in hepatocellular carcinoma.
    Gut. 2026 May 28:gutjnl-2026-338325. doi: 10.1136/gutjnl-2026-338325.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

23. WEXLER RP
    The Liver We Share.
    J Clin Oncol. 2026;44:1553-1554.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

24. AKUTA N, Kogiso T, Ikejima K, Otsuka M, et al
    Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
    J Gastroenterol. 2026;61:693-710.
    PubMed         Abstract available
    
    
25. KAWATA K, Takahashi H, Arai T, Seko Y, et al
    Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests.
    J Gastroenterol. 2026;61:783-795.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

26. SENGUL I, Sengul D
    Regarding IL-15 Plus Thymosin alpha1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
    J Gastroenterol Hepatol. 2026 May 29. doi: 10.1111/jgh.70471.
    PubMed         Abstract available
    
    
27. MATONO T, Tada T, Hiraoka A, Hirooka M, et al
    Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
    J Gastroenterol Hepatol. 2026 May 22. doi: 10.1111/jgh.70422.
    PubMed         Abstract available
    
    

    
    J Hepatol

28. XU Y, Yue T, Batbold U, Magassa A, et al
    MARCHF6 orchestrates hepatic lipid homeostasis by targeting SREBP1 for ER-associated degradation.
    J Hepatol. 2026 May 21:S0168-8278(26)00284-9. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
29. BARBON E, Simoni C, Argabright A, Boettiger M, et al
    Liver-directed lentiviral gene therapy confers durable hepatic and systemic amelioration of methylmalonic acidemia in mice.
    J Hepatol. 2026 May 25:S0168-8278(26)00288-6. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
30. CHEW V
    Neoadjuvant GOLP for high-risk resectable intrahepatic cholangiocarcinoma: Shifting the treatment paradigm?
    J Hepatol. 2026 May 29:S0168-8278(26)00286-2. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    

    
    N Engl J Med

31. LIANG F, Shi GM, Fan J
    Neoadjuvant GOLP in Intrahepatic Cholangiocarcinoma. Reply.
    N Engl J Med. 2026;394:2070-2071.
    PubMed        
    
    
32. AKKUS E
    Neoadjuvant GOLP in Intrahepatic Cholangiocarcinoma.
    N Engl J Med. 2026;394:2070.
    PubMed        
    
    

    
    Nat Rev Cancer

33. DIAZ-MUNOZ M
    An adenosine derivative for the treatment of hepatocellular carcinoma.
    Nat Rev Cancer. 2026 May 29. doi: 10.1038/s41568-026-00945.
    PubMed        
    
    

    
    Oncogene

34. WAN Q, Li J, Guo M, Hu J, et al
    GPX8(+) cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma.
    Oncogene. 2026 May 22. doi: 10.1038/s41388-026-03711.
    PubMed         Abstract available
    
    

    
    PLoS One

35. IYER A, Doornbos C, Evelo C, Kutmon M, et al
    GSEA and the coexpression network approach identify novel pathway connections of molecular processes affected in Porto-sinusoidal vascular disease.
    PLoS One. 2026;21:e0347338.
    PubMed         Abstract available
    
    
36. POH WY, Azzeri A, Zain SM, Mohamed R, et al
    Cost-effectiveness of various referral pathways to identify advanced fibrosis among type 2 diabetes mellitus patients with metabolic dysfunction-associated steatotic liver disease in primary care setting in Malaysia.
    PLoS One. 2026;21:e0350263.
    PubMed         Abstract available
    
    
37. KIM LY, Lee JS, Yoo JJ, Cho EJ, et al
    Machine learning-based prediction of hepatocellular carcinoma risk in steatotic liver disease: A nationwide cohort study.
    PLoS One. 2026;21:e0349593.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

38. HUANG X, Hao J, Wang S, Deng B, et al
    mRNA-laden LNP-enabled in situ CAR-macrophage alleviates liver fibrosis via inhibiting activated HSCs and modulating the immune microenvironment.
    Proc Natl Acad Sci U S A. 2026;123:e2534673123.
    PubMed         Abstract available
    
    

    
    Radiology

39. MITTELSTEIN DR, Khurana A, Vodkin I, Vavinskaya V, et al
    Interobserver Agreement in Contrast-enhanced US for Hepatic Nodules in Patients with Fontan-associated Liver Disease.
    Radiology. 2026;319:e252622.
    PubMed         Abstract available
    
    

    
    Transplant Proc

40. DE MACEDO PRA, Pessotto LGV, Teramoto FD, Loureiro JC, et al
    Hepatic Artery Thrombosis After Liver Transplantation: Treatment and Outcomes at a Brazilian Tertiary Center.
    Transplant Proc. 2026 May 28:S0041-1345(26)00214.
    PubMed         Abstract available
    
    

    
    Transplantation

41. THIERRY G, Piette B, Navez M, Koch JN, et al
    Oncologic Safety of Irradiated-only Autologous Blood Transfusion in Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Cohort Study.
    Transplantation. 2026 May 28. doi: 10.1097/TP.0000000000005760.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum